

# Central England Haemato- Oncology & Oncology Research Biobank (CEHRB)

REC reference: 09/H0405/12

## Annual Report April 2016 to March 2017

CEHRB C/o West Midlands Regional Genetics Laboratory  
Birmingham Women's Hospital Edgbaston, Birmingham, B15 2TG  
Tel: 0121 627 2710 | Fax: 0121 627 2711

<http://www.bwnft.nhs.uk/healthcare-professional/west-midlands-regional-genetics-laboratory/central-england-haemato-oncology-and-oncology-research-biobank>

## PART 1- Staff, Samples Stored and Patient Consent

- 1.1 CEHRB Staff
- 1.2 Steering Committee
- 1.3 Types of samples and material stored
- 1.4 Hospitals involved in requesting patient consent
- 1.5 Consented patient figures
  - 1.5.1 Cumulative figures for patient consent
  - 1.5.2 Patients consented from individual hospitals

## PART 2 - Projects and Publications 2016-2017

- 2.1 Existing Projects receiving samples from CEHRB between April 2016 and March 2017
- 2.2 Newly Approved projects that have received samples from CEHRB between April 2016 and March 2017
- 2.3 List of Publications/presentations (2016/2017) that have used samples from CEHRB

## PART 3 –Bank sustainability and Targets

- 3.1 Promotion of CEHRB
- 3.2 Sustainability of CEHRB
  
- 3.3 Review of Targets for 2016 - 2017
- 3.4 New Targets for 2017 - 2018

## PART 1- Staff, Samples Stored and Patient Consent

### 1.1 CEHRB Staff

The following staff members, from the West Midlands Regional Genetics Laboratory contribute to CEHRB activities.

#### *Director*

Prof Mike Griffiths      Email: [mike.griffiths@bwnft.nhs.uk](mailto:mike.griffiths@bwnft.nhs.uk)

#### *Manager and HTA Designated Individual*

Sally Jeffries              Email: [sally.jeffries@bwnft.nhs.uk](mailto:sally.jeffries@bwnft.nhs.uk)

#### *Scientific Support*

Louise Palm                Email: [louise.palm@bwnft.nhs.uk](mailto:louise.palm@bwnft.nhs.uk)

#### *Technical and Admin Support*

Kim Piechocki              Email: [kim.piechocki@bwnft.nhs.uk](mailto:kim.piechocki@bwnft.nhs.uk)

Dipika Patel                Email: [dipika.patel@bwnft.nhs.uk](mailto:dipika.patel@bwnft.nhs.uk)

#### *Health and Safety Officer*

Nigel Coles                Email: [nigel.coles@bwnft.nhs.uk](mailto:nigel.coles@bwnft.nhs.uk)

#### *Information and Technology Manager*

Gareth Masson            Email: [gareth.masson@bwnft.nhs.uk](mailto:gareth.masson@bwnft.nhs.uk)

## 1.2 Steering Committee

### ***Prof Charles Craddock (Chair and Representative for Cure Leukaemia)***

Consultant Haematologist  
Centre for Clinical Haematology  
University Hospital Birmingham NHS  
Foundation Trust  
Email: [charles.craddock@uhb.nhs.uk](mailto:charles.craddock@uhb.nhs.uk)

### ***Dr Richard Chasty (Lymphoma Group)***

University Hospital North Staffordshire  
Hilton Road  
Harpfields  
Stoke-on-Trent  
Staffordshire  
ST4 6SD  
E-mail: [Richard.Chasty@uhns.nhs.uk](mailto:Richard.Chasty@uhns.nhs.uk)

### ***Dr Guy Pratt (Myeloma Group)***

Consultant Haematologist  
Heartlands Hospital  
Bordesley Green East  
Birmingham  
West Midlands  
B9 5ST  
E-mail: [guy.pratt@heartofengland.nhs.uk](mailto:guy.pratt@heartofengland.nhs.uk)

### ***Dr Jeff Neilson (Ethics Representative)***

Consultant Haematologist  
Russell's Hall Hospital  
Dudley West Midlands  
DY1 2HQ  
E-mail: [jeff.neilson@dgoh.nhs.uk](mailto:jeff.neilson@dgoh.nhs.uk)

### ***Alan MacWhannell (Myeloid Group)***

Royal Wolverhampton Hospital  
Wolverhampton Road  
Heath Town  
Wolverhampton  
WV10 0QP  
E-mail: [Alan.MacWhannell@nhs.net](mailto:Alan.MacWhannell@nhs.net)

### ***Dr Mark Velangi (Pediatric Group)***

Birmingham Children's Hospital  
Steelhouse Lane  
Birmingham  
B4 6NH  
E-mail: [mark.velangi@bch.nhs.uk](mailto:mark.velangi@bch.nhs.uk)

### ***Kelly Hard (Research and Development)***

Research and Development Manager  
Birmingham Women's Hospital  
Edgbaston, Birmingham, B15 2TG  
Email: [Kelly.hard@bwnft.nhs.uk](mailto:Kelly.hard@bwnft.nhs.uk)

### ***Prof Mike Griffiths (CEHRB Director)***

West Midlands Regional Genetics Laboratory  
Birmingham Women's Hospital  
Edgbaston  
Birmingham B15 2TG  
Email: [mike.griffiths@bwnft.nhs.uk](mailto:mike.griffiths@bwnft.nhs.uk)

### ***Sally Jeffries (CEHRB Manager)***

West Midlands Regional Genetics Laboratory  
Birmingham Women's Hospital  
Edgbaston  
Birmingham B15 2TG  
Email: [sally.jeffries@bwnft.nhs.uk](mailto:sally.jeffries@bwnft.nhs.uk)

### ***Julian Borrow (WMRGL)***

West Midlands Regional Genetics Laboratory  
Birmingham Women's Hospital  
Edgbaston  
Birmingham B15 2TG  
Email: [Julian.Borrow@bwnft.nhs.uk](mailto:Julian.Borrow@bwnft.nhs.uk)

## 1.3 Types of samples and material stored

### *Samples*

- Peripheral Blood
- Marrow
- Solid tumour


### *Material from peripheral blood and marrow*

- Cytogenetic fixed cell suspensions
- DNA
- RNA/cDNA
- Fresh peripheral blood and marrow
- Plasma (on request)
- Other (on request)


### *Material from Solid tumours (by request only)*

- Fresh tissue
- FFPE slides

**Percentage of sample types released from CEHRB between April 2009-March 2017**



## Percentage of sample types released from CEHRB between April 2016-March 2017



### 1.4 Hospitals involved in seeking patient consent

There are 10 hospitals that have a part funded Research Nurse who is involved in seeking patient consent specifically for CEHRB

- Royal Stoke University Hospital, Staffordshire
- County Hospital, Stafford
- Queen Elizabeth Hospital, Birmingham
- Russell's Hall Hospital, Dudley
- Heartlands Hospital, Birmingham
- University Hospital Coventry
- Worcestershire Royal Hospital, Worcester
- Alexandra Hospital, Redditch
- Sandwell General Hospital, West Bromwich
- New Cross Hospital, Wolverhampton

We have also received patient consent from the following hospitals:


- BMI The Priory Hospital, Birmingham
- Nuffield Health Wolverhampton Hospital
- Mosely Hall Hospital, Birmingham
- Spire Little Aston Hospital, Sutton Coldfield
- Hereford County Hospital
- Princess Royal Hospital, Telford
- Kidderminster Hospital

## 1.5 Consented patient figures

The following data is based on consent data received from 11 sites:

Hospital List	
<b>ALBR</b>	Alexandra Hospital
<b>CHCB</b>	Centre for Clinical Haematology, Queen Elizabeth Hospital
<b>EBEB</b>	Heartlands Hospital
<b>KGKI</b>	Kidderminster General Hospital
<b>NXWV</b>	New Cross Wolverhampton
<b>RUDU</b>	Russell's Hall, Dudley
<b>SDMS</b>	Stafford District General
<b>SDSA</b>	Sandwell Health Care NHS Trust
<b>UHNS</b>	University Hospital North Staffordshire
<b>WGCO</b>	Walsgrave Hospital Coventry
<b>WRWO</b>	Worcester Royal

### 1.5.1 Cumulative patient consent since April 2008



- The total number of patients consented during 2016-2017 is **200**. The number of patients consenting has decreased by 68% since 2011, and 33% since last year. This reduction is likely to reflect the limited resources for consenting patients.


## 1.5.2 Patients consented from Individual Hospitals

Patient consent has predominantly been secured from Alexandra, Kidderminster, Russell's Hall and Worcester Royal hospitals during 2016-2017.

Number of patients consented per site:

	2008-11	2011-12	2012-13	2013-14	2014-15	2015-16	2016-17	Total between 2008-17
ALBR		2	34	41	44	57	48	226
CHCB		179	124	178	52	33	1	567
EBEB		12	35	0	5	0	1	53
KGKI		0	1	0	10	25	20	56
NXWV		190	179	70	122	69	5	635
RUDU		8	61	71	14	16	26	196
SDMS		136	97	141	86	3	1	464
SDSA		53	34	32	27	0	1	147
UHNS		16	0	7	11	6	0	40
WGCO		8	0	14	3	4	1	30
WRWO		19	14	12	76	61	93	275
Other*		0	0	0	22	25	3	50
<b>Grand Total</b>	<b>796</b>	<b>623</b>	<b>579</b>	<b>566</b>	<b>472</b>	<b>299</b>	<b>200</b>	<b>3535</b>

\*Other includes consents from unfunded centres but excludes BCCB (Paediatrics).





## PART 2: Projects and Publications

- The total number of samples sent out to ethically approved projects during April 2016 to March 2017 is **1022** (compared to 218 in 2015-16). Details are provided below.
  - **12** projects have received samples from CEHRB during this period.
    - 5 new projects and 7 existing projects.
  - **6** new projects were approved during this period.
- Since Sept 2009 CEHRB has provided **3862** samples to **65** projects. Some of these projects continue to receive samples.

## 2.1 Existing projects that have received samples from CEHRB between April 2016 and March 2017

Project No.	Principal Investigator	Laboratory Address	Sponsor	Samples Sent	
				Type	Number
3	Dr Tatjana Stankovic	CRUK Institute for Cancer Studies	Kay Kendall Leukaemia Fund	Blood	2
31	Prof Peter Cockerill & Constanze Bonifer	IBR Medical School, The University of Birmingham	Leukaemia and Lymphoma Research	Marrow	3
34	Dom McMullan	West Midlands Regional Genetics Laboratory, Birmingham Women's Hospital	Cytocell	Fixed Cells	226
42	Dr James Allan	Northern Institute for Cancer Research, Newcastle University	Leukaemia and Lymphoma Research	DNA	576
43	Dr Nicholas Davies	Institute of Cancer and Genomic Sciences, The University of Birmingham	Leukaemia and Lymphoma Research	Blood	5
				Marrow	3
60	Susanna Akiki	Department of Laboratory Medicine and Pathology, Hamad Medical Corporation, Qatar	Hamad Medical Corporation	cDNA	73
				DNA	51
63	Prof Peter Cockerill & Constanze Bonifer	Institute of Biomedical Research, The University of Birmingham	Bloodwise program grant	Marrow	6

## 2.2 Newly approved projects that have received samples from CEHRB Between April 2016 and March 2017

Project No.	Principal Investigator	Laboratory Address	Sponsor	Samples Sent	
				Type	Number
62	Dr Francis Mussai	School of Cancer Sciences, The University of Birmingham	CRUK and other grants	Marrow	1
				Blood	4
64	DR Steven Coles	Institute of Science and the Environment, University of Worcester	No	Marrow	2
				Blood	2
65	David Grimwade & Sylvie Freeman	Dept. of Medical & Molecular Genetics, Guy's Hospital, London	NIHR	DNA	11

<b>66</b>	Sally Jeffries & Miss Melissa Connolly	West Midlands Regional Genetics Laboratory, Birmingham Women's Hospital	Trainee Funding - LETB	RNA	53
<b>68</b>	Prof Nicholas Cross	Wessex Regional Genetics Laboratory, Salisbury District Hospital	Bloodwise	DNA	4

## 2.3 List of publications/presentations that have used samples from CEHRB

- Since 2009 there have been **20** publications and at least 12\* oral presentations/posters that have used samples received from CEHRB. (\* data on oral presentations collated since 2010).
- There have been **2** publication during the 2016-2017 period, detailed below.

### *Publications (2016/2017)*

1. Mutational analysis of disease relapse in patients allografted for acute myeloid leukemia. *Lynn Quek,1-3,\* Paul Ferguson,4,5,\* Marlen Metzner,1,3 Ikhlmaq Ahmed,5 Alison Kennedy,1,3 Catherine Garnett,1,3 Sally Jeffries,6 Claudia Walter,7 Kim Piechocki,6 Adele Timbs,8 Robert Danby,2,3 Manoj Raghavan,4 Andrew Peniket,2,3 Mike Griffiths,6 Andrew Bacon,4 Janice Ward,4 Keith Wheatley,5 Paresh Vyas,1-3,† and Charles Craddock4,5,†*. Blood Advances. 2016 Dec 27; 1(3):193-204
2. Characterisation of the Genomic Landscape of CRLF2-rearranged Acute Lymphoblastic Leukemia. *Lisa J Russell1\*, Lisa Jones1, Amir Enshaei1, Stefano Tonin1, Sarra L Ryan1, Jeyanthi Eswaran1, Sirintra Nakjang2, Elli Papaemmanuil3,4, Jose M C Tubio4, Adele K Fielding5, Ajay Vora6, Peter J Campbell4, Anthony V Moorman1, and Christine J Harrison1*. Genes Chromosomes Cancer. 2017 May; 56(5):363-372

## PART 3: Targets

### 3.1. Promotion of the Biobank

- Due to very limited resources the biobank has not undertaken any promotional work this year
- The biobank is present on the following biobank registries;
  - NCRI Confederation of Cancer Biobanks
    - <http://ccb.ncri.org.uk/>
  - Orphanet
    - <http://www.orpha.net>

### 3.2. Sustainability of CEHRB

The biobank has yet to become sustainable. Funding is still to be sought.

### 3.3. Review of targets and other achievements for 2016-2017

#### *Targets Achieved*

- Approve and supply samples to at least 5 projects
  - 6 new projects approved in period


#### *Targets Not Achieved*

- Ensure continued improvement in patient recruitment by liaising with RRN.
- Secure additional funding
- Seek to establish further collaboration with global Biobank networks to increase income and research portfolio.

Targets not achieved due to very limited staff resources.

### 3.4. New targets for 2017-2018

- Secure additional funding is the main priority
  - Seek to establish further collaboration with global Biobank networks to increase income and research portfolio.
  - Seek and submit grants for biobank funding
- Approve and supply samples to at least 5 projects
- Ensure continued patient consent by liaising with RRN.



Sally Jeffries BSc(Hons) FRCPath | Principal Clinical Scientist  
Deputy Head of Haemato-Oncology Genetics and Manager of CEHRB